ATE392474T1 - 84p2a9: prostata- und testis-spezifisches protein das hohe expression in prostatakrebs aufweist - Google Patents

84p2a9: prostata- und testis-spezifisches protein das hohe expression in prostatakrebs aufweist

Info

Publication number
ATE392474T1
ATE392474T1 AT01910358T AT01910358T ATE392474T1 AT E392474 T1 ATE392474 T1 AT E392474T1 AT 01910358 T AT01910358 T AT 01910358T AT 01910358 T AT01910358 T AT 01910358T AT E392474 T1 ATE392474 T1 AT E392474T1
Authority
AT
Austria
Prior art keywords
prostate
high expression
specific protein
exhibiting high
protein exhibiting
Prior art date
Application number
AT01910358T
Other languages
German (de)
English (en)
Inventor
Aya Jakobovits
Daniel Afar
Pia Challita-Eid
Elana Levin
Steve Mitchell
Rene Hubert
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Application granted granted Critical
Publication of ATE392474T1 publication Critical patent/ATE392474T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01910358T 2000-01-26 2001-01-26 84p2a9: prostata- und testis-spezifisches protein das hohe expression in prostatakrebs aufweist ATE392474T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17856000P 2000-01-26 2000-01-26

Publications (1)

Publication Number Publication Date
ATE392474T1 true ATE392474T1 (de) 2008-05-15

Family

ID=22653018

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01910358T ATE392474T1 (de) 2000-01-26 2001-01-26 84p2a9: prostata- und testis-spezifisches protein das hohe expression in prostatakrebs aufweist
AT08154530T ATE501255T1 (de) 2000-01-26 2001-01-26 84p2a9: prostata- und hodenspezifisches protein, das sehr stark bei prostatakrebs vorkommt

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT08154530T ATE501255T1 (de) 2000-01-26 2001-01-26 84p2a9: prostata- und hodenspezifisches protein, das sehr stark bei prostatakrebs vorkommt

Country Status (12)

Country Link
US (3) US7510855B2 (https=)
EP (2) EP1250434B1 (https=)
JP (2) JP3946044B2 (https=)
AT (2) ATE392474T1 (https=)
AU (2) AU3797301A (https=)
CA (1) CA2398064C (https=)
CY (1) CY1111522T1 (https=)
DE (2) DE60133627T2 (https=)
DK (1) DK1967586T3 (https=)
ES (2) ES2304126T3 (https=)
IL (2) IL150873A0 (https=)
WO (1) WO2001055391A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1250434B1 (en) * 2000-01-26 2008-04-16 Agensys, Inc. 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US9493562B2 (en) 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
SG11201501646PA (en) * 2012-09-07 2015-04-29 Agency Science Tech & Res Peptides and their uses
WO2022013154A1 (en) * 2020-07-14 2022-01-20 Myneo Nv Method, system and computer program product for determining presentation likelihoods of neoantigens

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
TR199902053T2 (xx) * 1997-02-25 2000-04-21 Corixa Corporation Prostat kanserinin immunoterapisine y�nelik bile�ikler ve bunlar�n kullan�lmas�na matuf metodlar.
EP0973898A2 (en) 1997-04-10 2000-01-26 Genetics Institute, Inc. SECRETED EXPRESSED SEQUENCE TAGS (sESTs)
EP1053319A2 (en) 1998-01-28 2000-11-22 Chiron Corporation Human genes and gene expression products ii
US6013450A (en) 1998-02-20 2000-01-11 Incyte Pharmaceuticals, Inc. CAF1-related protein
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
EP1074617A3 (en) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
WO2001051628A2 (en) 2000-01-14 2001-07-19 Millennium Pharmaceuticals, Inc. Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP1250434B1 (en) * 2000-01-26 2008-04-16 Agensys, Inc. 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
CA2395872A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001249642A1 (en) 2000-04-06 2001-10-23 Genetics Institute, Llc Polynucleotides encoding novel secreted proteins
CN1328147A (zh) 2000-06-12 2001-12-26 上海博德基因开发有限公司 一种新的多肽——人磷脂酶49.06和编码这种多肽的多核苷酸
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
AU2002210791A1 (en) 2000-07-28 2002-02-13 Compugen Inc. Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
AU2001290548A1 (en) 2000-09-11 2002-03-26 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1325120A4 (en) 2000-10-12 2005-05-25 Nuvelo Inc NUCLEIC ACIDS AND POLYPEPTIDES
AU2002253878A1 (en) 2001-01-25 2002-08-06 Gene Logic, Inc. Gene expression profiles in breast tissue

Also Published As

Publication number Publication date
AU3797301A (en) 2001-08-07
ES2304126T3 (es) 2008-09-16
US20040126862A1 (en) 2004-07-01
DK1967586T3 (da) 2011-06-20
AU2001237973B2 (en) 2006-09-07
US7510855B2 (en) 2009-03-31
CA2398064C (en) 2012-12-18
WO2001055391A3 (en) 2002-02-21
ES2360155T3 (es) 2011-06-01
US8013126B2 (en) 2011-09-06
JP3946044B2 (ja) 2007-07-18
ATE501255T1 (de) 2011-03-15
JP2003520605A (ja) 2003-07-08
CY1111522T1 (el) 2015-08-05
CA2398064A1 (en) 2001-08-02
DE60133627T2 (de) 2009-07-30
EP1967586B1 (en) 2011-03-09
DE60133627D1 (de) 2008-05-29
DE60144204D1 (de) 2011-04-21
US20090170191A1 (en) 2009-07-02
US20070054363A1 (en) 2007-03-08
US7582448B2 (en) 2009-09-01
JP5501550B2 (ja) 2014-05-21
IL150873A0 (en) 2003-02-12
IL150873A (en) 2010-02-17
EP1967586A1 (en) 2008-09-10
EP1250434B1 (en) 2008-04-16
WO2001055391A2 (en) 2001-08-02
JP2006325595A (ja) 2006-12-07
EP1250434A2 (en) 2002-10-23

Similar Documents

Publication Publication Date Title
WO2005062972A3 (en) Treatment of cancer with novel anti-il 13 monoclonal antibodies
PT1349870E (pt) Composições para a terapêutica e diagnóstico do cancro do ovário
DK1992695T3 (da) Lectin-transmembran-antigen af type C udtrykt i human prostatacancer og avendelser deraf
ATE529535T1 (de) Genexpressionsprofilierung in einer biopsie unterzogenem tumorgewebe
NZ330887A (en) Monoclonals and polyclonals antibodies for the diagnosis of breast cancer
TR200001646T2 (tr) Bir salgılanmış meme kanseri proteini olan mamaglobin.
BR0010702A (pt) Novas quinonas como terapias de doenças
DE60126495D1 (de) Nukleinsäure und protein, genannt 158p1d7, für die behandlung und erkennung von blasenkrebs und anderen krebsarten
WO1998045328A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
CY1111522T1 (el) 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker
DE60130541D1 (de) Gewebe-spezifische protein 103p2d6, hochexprimiert in verschiedene krebsarten
ATE403716T1 (de) Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen
WO2001096391A3 (en) 55p4h4: gene expressed in various cancers
WO2001059110A3 (en) 34p3d7: a tissue specific protein highly expressed in prostate cancer
WO2003020954A3 (en) 205p1b5 in treatment and detection of cancer
WO2001059115A3 (en) 83p5g4: a tissue specific protein highly expressed in prostate cancer
WO2002088380A3 (en) Immunogenic tumor antigens: nucleic acids and polypeptides encoding the same and methods of use thereof
WO2001075010A3 (fr) Nouveau polypeptide, proteine humaine de transduction nucleaire 25 contenant un domaine structurel atp/gtp, et polynucleotide codant pour ce polypeptide
WO2001075001A3 (en) A novel polypeptide, cyclic adenosine 9-dependant human protein kinase and the polynucleotide encoding the polypeptide
WO2001075059A3 (fr) Nouveau polypeptide, proteine humaine 11 de regulation de gtp, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1250434

Country of ref document: EP